Strategies to Identify Needs and Coordinate Referrals to a Multidisciplinary Chronic Graft-Versus-Host Disease Clinic

Chronic graft-versus-host disease (GVHD) is a potentially serious complication that significantly impacts quality of life in patients undergoing allogeneic hematopoietic cell transplant.  Treatment of chronic GVHD can be optimized by providing coordinated care involving a multidisciplinary team preferably in medical centers which have access to specialized GVHD clinics. A thorough understanding of the various clinical manifestations of chronic GVHD and National Institutes of Health recommendations for the diagnosis, treatment, and supportive care of these patients is essential for the early recognition of signs and symptoms which in turn can facilitate referrals to a multidisciplinary chronic GVHD clinic.  Hematology/oncology nurses require ongoing education that would provide the expert guidance necessary for the optimal management of patients with chronic GVHD.


This information was originally presented at the NCCN 2018 Nursing Forum: Oncology Nursing in Hematologic Malignancies held in New York, New York, on September 21, 2018.

Target Audience

This educational program is designed to meet the educational needs of oncology nurses who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Describe the clinical manifestations of chronic GVHD.
  • Review the current standard of care and emerging treatment options for chronic GVHD.
  • Develop a treatment plan incorporating strategies for early detection and supportive care interventions to improve the outcomes of patients with chronic GVHD.
Additional information

This activity is supported by educational grants from:

  • Celgene Corporation
  • Genentech
  • Jazz Pharmaceuticals, Inc.
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

This educational activity is supported by a medical education grant from Karyopharm Therapeutics.

This educational activity is supported by an independent educational grant from Incyte.

This educational activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs.

Course summary
Available credit: 
  • 0.50 ANCC contact hours
  • 0.50 Participation
Course opens: 
Course expires: 

Diane Hill-Polerecky, RN, MSN, BMTCN         
Fred and Pamela Buffett Cancer Center


Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education (CE) activities are expected to disclose any relevant financial relationships with a commercial interest as defined by ACCME’s, ACPE’s, and ANCC’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity. 


NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship. 

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.  

Faculty Disclaimers 

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery. 

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses no relevant financial relationships:

Diane Hill-Polerecky, RN, MSN, BMTCN

NCCN Staff Disclosures 

The NCCN Activity Planning staff listed below discloses no relevant financial relationships: 

Robert W. Carlson, MD; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa G. Kimbro, MBA, CPA (employed by NCCN until August 10, 2018); Joan S. McClure, MS (employed by NCCN until August 1, 2018); Lisa Perfidio, MS; Shannon Ryan; Kathy Ann Smith, CMP, CHCP; Gary J. Weyhmuller, MBA, SPHR  

The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:

Donald Harting, ELS, CHCP
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options

Katherine Pierce
Pfizer Inc.: Equity Interest/Stock Options
Boston Scientific Corporation: Equity Interest/Stock Options 

The NCCN Clinical staff listed below discloses no relevant financial relationships: 

Mary A. Dwyer, MS, CGC; Hema Sundar, PhD

National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

NCCN designates this educational activity for a maximum of 0.50 contact hours.

Available Credit

  • 0.50 ANCC contact hours
  • 0.50 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader or other PDF reader software for certificate viewing/printing